Page last updated: 2024-12-06

pyriminil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

pyriminil: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID40813
CHEMBL ID1528242
SCHEMBL ID146250
MeSH IDM0059727

Synonyms (46)

Synonym
AC-12692
53558-25-1
MLS001232711
smr000678267
1-(4-nitrophenyl)-3-(pyridin-3-ylmethyl)urea
1-(4-nitrophenyl)-3-(3-pyridylmethyl)urea
urea, n-(4-nitrophenyl)-n'-(3-pyridinylmethyl)-
einecs 258-626-7
dlp 787
epa pesticide chemical code 104501
hsdb 6460
pyrinuron
1-(4-nitrophenyl)-n'-(3-pyridinylmethyl)urea
one time
n-(4-nitrophenyl)-n'-(3-pyridinylmethyl)urea
vacor
brn 0490322
pyrinuron [ansi]
rh-787
caswell no. 718b
1-(3-pyridylmethyl)-3-(4-nitrophenyl)urea
pyriminyl
urea, 1-nitrophenyl-3-(3-pyridylmethyl)-
pyriminil
n-3-pyridylmethyl-n'-p-nitrophenylurea
STK494478
AKOS003356375
NCGC00247371-01
tox21_302252
cas-53558-25-1
dtxsid1042360 ,
dtxcid9022360
NCGC00255836-01
HMS2968P19
q7bgs137yp ,
5-22-09-00313 (beilstein handbook reference)
unii-q7bgs137yp
pyrinuron [hsdb]
pyriminil [mi]
dlp-787
SCHEMBL146250
3-pyridylmethyl-3-(4-nitrophenyl)urea
n-(4-nitrophenyl)-n'-(3-pyridylmethyl)-urea
CHEMBL1528242
n-3-pyridylmethyl-n'-p-nitrophenyl urea
Q7263605

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" However, a bilateral toxic retinal vasculopathy, consisting of a severe generalized vasoconstriction and mild macular edema, occurred within three weeks."( Ocular ergotamine tartrate toxicity during treatment of Vacor-induced orthostatic hypotension.
Franklin, B; Mindel, JS; Rubenstein, AE, 1981
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (14)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
SMAD family member 2Homo sapiens (human)Potency54.94100.173734.304761.8120AID1346859; AID1346924
SMAD family member 3Homo sapiens (human)Potency54.94100.173734.304761.8120AID1346859; AID1346924
TDP1 proteinHomo sapiens (human)Potency14.58100.000811.382244.6684AID686979
AR proteinHomo sapiens (human)Potency27.53570.000221.22318,912.5098AID743035
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency36.22670.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency24.33650.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency34.37620.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency11.61170.000817.505159.3239AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency70.68190.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259403
aryl hydrocarbon receptorHomo sapiens (human)Potency21.64500.000723.06741,258.9301AID743085; AID743122
activating transcription factor 6Homo sapiens (human)Potency61.64480.143427.612159.8106AID1159516
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency66.67120.000323.4451159.6830AID743065; AID743067
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency79.43280.050127.073689.1251AID588590
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency22.38720.00419.962528.1838AID2675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-199039 (75.00)18.7374
1990's4 (7.69)18.2507
2000's1 (1.92)29.6817
2010's4 (7.69)24.3611
2020's4 (7.69)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 21.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index21.56 (24.57)
Research Supply Index4.04 (2.92)
Research Growth Index5.02 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (21.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.82%)5.53%
Reviews2 (3.64%)6.00%
Case Studies15 (27.27%)4.05%
Observational0 (0.00%)0.25%
Other37 (67.27%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]